Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safe ...

Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...

ORLANDO, Fla. — The Florida Department of Health held its first public workshop Friday on the subject of changing state rules regarding vaccines. It’s part of an ongoing push led by the state’s ...

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This ...

European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.

Researchers have discovered how acids on the surface of bacteria give these microscopic organisms their characteristic "rod" ...

Protons and neutrons—the building blocks of matter—belong to a huge class of particles called hadrons. Hadrons are composite ...

Mirum Pharmaceuticals, Inc. , a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress ...